Czech National Bank Buys 26,353 Shares of Bristol-Myers Squibb (NYSE:BMY)

Czech National Bank increased its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 6.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 466,102 shares of the biopharmaceutical company’s stock after acquiring an additional 26,353 shares during the quarter. Czech National Bank’s holdings in Bristol-Myers Squibb were worth $28,428,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the business. Mirador Capital Partners LP raised its holdings in Bristol-Myers Squibb by 1.7% during the first quarter. Mirador Capital Partners LP now owns 48,166 shares of the biopharmaceutical company’s stock worth $2,938,000 after buying an additional 812 shares during the last quarter. Winthrop Advisory Group LLC acquired a new position in Bristol-Myers Squibb during the first quarter worth $210,000. Parallel Advisors LLC raised its holdings in Bristol-Myers Squibb by 1.4% during the first quarter. Parallel Advisors LLC now owns 35,322 shares of the biopharmaceutical company’s stock worth $2,154,000 after buying an additional 471 shares during the last quarter. Tompkins Financial Corp raised its holdings in Bristol-Myers Squibb by 2.5% during the first quarter. Tompkins Financial Corp now owns 9,151 shares of the biopharmaceutical company’s stock worth $558,000 after buying an additional 225 shares during the last quarter. Finally, Partnership Wealth Management LLC raised its holdings in Bristol-Myers Squibb by 1.3% during the first quarter. Partnership Wealth Management LLC now owns 28,225 shares of the biopharmaceutical company’s stock worth $1,721,000 after buying an additional 358 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Piper Sandler assumed coverage on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. They set an “overweight” rating and a $65.00 price objective on the stock. UBS Group reduced their target price on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research note on Friday, April 11th. Argus upgraded shares of Bristol-Myers Squibb to a “hold” rating in a research note on Friday, April 25th. Jefferies Financial Group reduced their target price on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research note on Wednesday, April 23rd. Finally, William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $58.00.

Insider Buying and Selling at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 4,250 shares of the company’s stock in a transaction on Friday, April 25th. The shares were acquired at an average cost of $47.58 per share, with a total value of $202,215.00. Following the completion of the acquisition, the executive vice president now directly owns 83,513 shares in the company, valued at $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Price Performance

BMY opened at $48.26 on Friday. The firm has a market cap of $98.21 billion, a P/E ratio of -10.92, a PEG ratio of 2.07 and a beta of 0.39. The firm has a 50-day moving average of $50.49 and a 200 day moving average of $55.37. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $63.33.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm’s revenue for the quarter was down 5.6% on a year-over-year basis. During the same quarter in the prior year, the business earned ($4.40) earnings per share. On average, research analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Shareholders of record on Friday, April 4th were issued a dividend of $0.62 per share. This represents a $2.48 annualized dividend and a yield of 5.14%. The ex-dividend date of this dividend was Friday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 92.88%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.